Table 1.
Association of targeted therapies and hepatitis C virus reactivation
| Targeted therapy | Increased HCV viral load | HCV related hepatic flare | Liver function test follow-up | HCV RNA follow-up |
| Anti-CD antibodies | ||||
| Rituximab | Yes, in case series | May cause, further studies are needed | Yes | Yes, especially in high risk patients |
| Alemtuzumab | Yes, in one case report | Yes, in one case report | Yes | Yes |
| Brentuximab | No data in literature | No data in literature | No | No |
| Tyrosine kinase inhibitors: | ||||
| Imatinib | HBV reactivation in CML patients, insufficient data related to HCV | No (possibly in HBV infected patients) | Yes (DIH) | No |
| Sorafenib | No, on the contrary in some cases sorafenib may have a suppressive effect on HCV viral load | No | No (DIH) | No |
| Crizotinib | US | US | Yes, may cause dose dependent hepatitis | No |
| Pazopanib | US | US | Yes (DIH) | No |
| Lapatinib | No | No | Yes (DIH) | No |
| mTOR inhibitors: | ||||
| Everolimus | Maybe (2 cases of HBV reactivation in the literature) | Yes (In phase 3 trial as a side effect) | Yes | No |
| Anti-Her2 Ab: | ||||
| Trastuzumab | No | No | No | No |
| Pertuzumab | No | No | No | No |
| Anti-EGFR therapies: | ||||
| Cetuximab | US | US | No | No |
| Panitumumab | US | US | No | No |
| Immunomodulating Ab: | ||||
| Ipilimumab | No (Two cases of HCV infected patients were safely treated) | No | Yes (DIH) | No |
Ab: Antibodies; US: Unspecified; DIH: Drug induced hepatotoxicity; HCV: Hepatitis C virus.